Top Markets
Coin of the day
AP Biosciences Inc AP Biosciences Inc

AP Biosciences Inc

6945
Classifica tra le azioni #16392
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company... AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
Prezzo delle azioni
$3.06
Capitalizzazione di mercato
$296.40M
Variazione (1 giorno)
-2.24%
Variazione (1 anno)
-22.64%
Paese
TW
Scambia AP Biosciences Inc (6945)

Categoria

Cronologia dei frazionamenti azionari per AP Biosciences Inc (6945)
L’azione AP Biosciences Inc (simbolo: 6945) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Sep 02, 2026.
Una quota di 6945 acquistata prima di Sep 02, 2026 equivale oggi a 0 quote di 6945.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH